Recent decades have seen a marked rise in the prevalence of metabolic diseases—particularly obesity, diabetes mellitus, and thyroid disorders—posing growing public health challenges. Traditional pharmacologic approaches remain central to management but are constrained by adverse effects and the emergence of drug resistance. Immune checkpoint molecules, initially studied for their pivotal role in cancer immunotherapy, are now recognized as regulators of metabolic homeostasis. This review synthesizes current mechanistic evidence that immune checkpoint pathways integrate immune regulation with energy metabolism and inflammation and considers translational implications for metabolic disease therapy.
Immune checkpoints are surface molecules and signaling pathways that modulate immune cell activation, tolerance, and exhaustion. Beyond their immunomodulatory roles in oncology, mounting research indicates these pathways influence systemic and tissue-level metabolic processes. By shaping inflammatory responses and cellular metabolic programs, checkpoint signaling can affect insulin sensitivity, adipose tissue function, and endocrine organ homeostasis. The review emphasizes that immune checkpoint pathways operate at the intersection of immunity and metabolism, mediating cross-talk between immune cells (for example, T cells and macrophages) and parenchymal tissues involved in metabolic regulation.
Among immune checkpoint pathways, the PD-1/PD-L1 axis is repeatedly highlighted for dual roles in immune control and metabolic modulation. In the context of obesity, PD-1/PD-L1 signaling can influence adipose tissue inflammation by altering macrophage phenotypes. Specifically, activation of this pathway has been associated with polarization of adipose tissue macrophages away from a proinflammatory M1 state toward an anti-inflammatory M2 phenotype. This shift may attenuate chronic low-grade inflammation that characterizes obesity and contributes to metabolic dysfunction. The review presents these mechanistic insights as evidence that checkpoint modulation could ameliorate obesity-associated inflammation and its metabolic consequences.
Immune checkpoint pathways also appear relevant to diabetes pathophysiology, although details in the abstract are limited. By regulating inflammatory milieu and immune cell activity in metabolic organs, checkpoint signaling could impact insulin resistance and pancreatic islet inflammation. The authors note growing interest in leveraging immune checkpoint modulation to address the immune-mediated components of diabetes, but they indicate that comprehensive mechanistic and translational studies remain lacking compared with oncology research.
The review extends the discussion of immune checkpoint involvement to thyroid disorders, suggesting that checkpoint pathways may influence thyroid immune regulation and metabolic consequences. As with obesity and diabetes, the authors synthesize evidence that immune checkpoints contribute to the balance between proinflammatory and regulatory immune responses within endocrine tissues. Specific mechanistic details and clinical data for thyroid disease are not provided in the abstract, underscoring the need for deeper investigation.
Given the mechanistic links between immune checkpoint signaling and metabolic regulation, the authors propose immune checkpoint modulation as a novel therapeutic strategy for metabolic diseases. They present the repurposing of insights and agents from cancer immunotherapy as a conceptual framework for developing interventions that could correct aberrant immune–metabolic interactions. However, the review also cautions that the role of immune checkpoints in metabolic disease is underexplored; more preclinical and clinical research is required to define safety, efficacy, dosing, target selection, and potential adverse effects when applying checkpoint-directed approaches outside oncology.
The authors emphasize several areas requiring further work: comprehensive mechanistic studies to map checkpoint impacts across metabolic tissues; translational research to evaluate checkpoint-targeting agents in metabolic disease models; and clinical trials to assess therapeutic benefit and risks in patients with obesity, diabetes, or thyroid disorders. The abstract signals that existing literature is suggestive but incomplete, and that systematic reviews and integrated experimental–clinical programs are needed to move from concept to practice.
Immune checkpoint pathways, particularly PD-1/PD-L1, represent an emerging interface between immune regulation and metabolic homeostasis. Evidence summarized in the review supports a role for checkpoint signaling in modulating adipose tissue inflammation and broader metabolic dysfunction. While these insights create an attractive rationale for checkpoint-targeted therapies in metabolic diseases, the field remains nascent and underinvestigated compared with oncology. The authors call for expanded mechanistic and translational research to determine whether immune checkpoint modulation can be a safe and effective therapeutic approach for obesity, diabetes, and thyroid disorders.
(Conflict of interest: the authors declare no competing interests; one author is an editorial board member of the publishing journal but was not involved in manuscript handling.)